Moreover, we confirmed in independent cancer mRNA expression patient cohorts that MYCN immune anti-correlation is not restricted to NB, but it is a feature also of other malignancies (small cell lung cancer, rhabdomyosarcoma, Wilms’ tumor, retinoblastoma, acute myeloid leukemia, and T-acute lymphoid leukemia) (4). This evidence concerns the gene MYCN and neuroblastoma.